Press Releases

Subscribe
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nov 14, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 30 September 2025

Regulatory
Read more
Nov 13, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research

Read more
Oct 23, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Regulatory
Read more
Sep 19, 2025
2025
Press Release Non-regulatory

Elicera clarifies status of the iTANK-platform patent application in the U.S.

Read more
Aug 29, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 30 June 2025

Regulatory
Read more
Aug 25, 2025
2025
Press Release Non-regulatory

Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy

Read more
Aug 25, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee’s Assessment in Cohort 2

Read more
Jun 11, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics postpones final reporting of ELC-100 study due to database transition

Read more
May 28, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company’s oncolytic virus candidates, ELC-100 and ELC-201

Read more
May 27, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics' CEO sells a small portion of his shareholding – remains a long-term major shareholder with strong confidence in the company’s future

Read more
May 22, 2025
2025
Press Release Non-regulatory

Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy

Read more
May 15, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 31 March 2025

Regulatory
Read more
Apr 10, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee’s assessment of cohort 1

Read more
Apr 4, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics' Chief Scientific Officer invited to speak at the Swedish Cancer Research Meeting 2025 on May 22

Read more
Mar 20, 2025
2025
Press Release Regulatory

Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2

Regulatory
Read more
Mar 13, 2025
2025
Press Release Regulatory

Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters

Regulatory
Read more
Mar 7, 2025
2025
Press Release Regulatory

The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025

Regulatory
Read more
Feb 28, 2025
2025
Press Release Non-regulatory

Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics

Read more
Feb 28, 2025
2025
Press Release Non-regulatory

Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics

Read more
Feb 25, 2025
2025
Press Release Regulatory

Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million

Regulatory
Read more

Sign up for Press Releases

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.